A highly sensitive SERS quenching nanosensor for the determination of Tumor necrosis factor alpha in blood

Publication date: Available online 13 February 2020Source: Sensors and Actuators B: ChemicalAuthor(s): Mahnaz D. Gholami, Prashant Sonar, Godwin A. Ayoko, Emad L. IzakeAbstractTumor necrosis factor alpha (TNF-α) is a cytokine that plays a critical role in medical conditions such cardiovascular diseases, rheumatoid arthritis, inflammatory bowel disease, Alzheimer’s and cancer. Herein, we present a new method for the determination of TNF-α by surface enhanced Raman spectroscopy (SERS). A new benzothiazole azo dye (BAN) was used as a Raman probe to detect the cytokine after its selective extraction from blood plasma using a target-specific antibody-functionalised extractor chip. The disulfide bond structure of the extracted TNF-α was reduced to generate free sulfhydryl (SH), terminal groups that adsorb preferentially onto a BAN-functionalised SERS substrate and displace the BAN Raman reporter on the substrate surface. This causes the SERS spectrum of BAN to quench proportionally with the cytokine concentration. Using this SERS quenching sensor, TNF-α was quantified down to 1 × 10-14 M (173 pg/L). The quantification of the cytokine by the SERS quenching method was cross-validated against enzyme-linked immunosorbent assay (ELISA) and the percent agreement between the two measurements was found to be 93.39 %. Since many proteins and peptides have disulfide bonds in their molecular structures, the new SERS quenching method can...
Source: Sensors and Actuators B: Chemical - Category: Chemistry Source Type: research

Related Links:

This report provides an in-depth look at public drug program spending in Canada, using the Canadian Institute for Health Information's (CIHI) National Prescription Drug Utilization Information System. Public drug program spending does not include spending on drugs dispensed in hospitals or on those funded through cancer agencies and other special programs. Public drug program spending increased by 6.8% in 2018, compared to an increase of 5.3% in 2017. The growth in 2018 was largely because of the introduction of Ontario Health Insurance Plan+ (OHIP+), which extended drug coverage to all Ontario residents age 24 years or y...
Source: Healthcare Quarterly - Category: International Medicine & Public Health Source Type: research
  Cannabis, weed, marijuana, pot. It goes by several names, but we all know what it smells like. As weed becomes more mainstream, we on the Not Crazy podcast want to know: Is marijuana really an effective treatment for anxiety? Is it just a coping mechanism? Or a vice? In today’s podcast, Gabe and Jackie look at the research and weigh out the evidence. They also interview Eileen Davidson, a rheumatoid arthritis patient who regularly uses marijuana as a medicine to see what she has to say. What’s your take? Tune in for an open-minded discussion about weed. (Transcript Available Below) SUBSCRIBE &REV...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Anxiety and Panic General Medications Not Crazy Podcast Source Type: blogs
Hairy, scary, funny looking or pretty cool. The beasts in the Harry Potter universe are quite the diverse bunch with unique abilities and qualities. Just like new digital health tech targeted to fight autoimmune diseases or for the main part: their symptoms. Source: Warner Bros. Framestore The common ground for completely different illnesses like type 1 diabetes, inflammatory bowel disease, rheumatoid arthritis, and multiple sclerosis is an immune system disfunction. Immune cells and mechanisms target the body’s own cells and structures, deconstructing it bit by bit and inducing inflammation. An estim...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Biotechnology Future of Medicine chatbot diabetes digital health sleep optimization chronic pain chronic illness skin coronavirus autoimmune disease Source Type: blogs
Abstract New therapeutic approaches for chronic inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis, and psoriasis are needed because current treatments are often suboptimal in terms of both efficacy and the risks of serious adverse events. Inhibitor of apoptosis proteins (IAPs) are E3 ubiquitin ligases that inhibit cell death pathways and are themselves inhibited by second mitochondria-derived activator of caspases (SMAC). SMAC mimetics (SMs), small-molecule antagonists of IAPs, are being evaluated as cancer therapies in clinical trials. IAPs are also crucial regulators of inflammatory ...
Source: Science Signaling - Category: Biomedical Science Authors: Tags: Sci Signal Source Type: research
New therapeutic approaches for chronic inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis, and psoriasis are needed because current treatments are often suboptimal in terms of both efficacy and the risks of serious adverse events. Inhibitor of apoptosis proteins (IAPs) are E3 ubiquitin ligases that inhibit cell death pathways and are themselves inhibited by second mitochondria-derived activator of caspases (SMAC). SMAC mimetics (SMs), small-molecule antagonists of IAPs, are being evaluated as cancer therapies in clinical trials. IAPs are also crucial regulators of inflammatory pathways because t...
Source: Signal Transduction Knowledge Environment - Category: Science Authors: Tags: STKE Reviews Source Type: news
AbstractPurpose of ReviewBoth the chronic inflammation in inflammatory bowel disease (IBD), and its treatment, can increase the risk of malignancy. There is also an increasing number of patients with current and prior cancer who require IBD treatment. Thus, there is a complex interplay between immunosuppressive treatment and monitoring for new and recurrent cancer.Recent FindingsVedolizumab and ustekinumab have not been shown to increase the risk of malignancy. Transplant data shows a potential risk with tofacitinib although rheumatoid arthritis data does not. IBD patients have been shown to tolerate chemotherapy, specific...
Source: Current Gastroenterology Reports - Category: Gastroenterology Source Type: research
Choi The integration of computational techniques into drug development has led to a substantial increase in the knowledge of structural, chemical, and biological data. These techniques are useful for handling the big data generated by empirical and clinical studies. Over the last few years, computer-aided drug discovery methods such as virtual screening, pharmacophore modeling, quantitative structure-activity relationship analysis, and molecular docking have been employed by pharmaceutical companies and academic researchers for the development of pharmacologically active drugs. Toll-like receptors (TLRs) play a vital ...
Source: Molecules - Category: Chemistry Authors: Tags: Review Source Type: research
CONCLUSIONS: High-certainty evidence suggests that tofacitinib is superior to placebo for maintenance of clinical and endoscopic remission at 52 weeks in participants with moderate-to-severe UC in remission. The optimal dose of tofacitinib for maintenance therapy is unknown. High-certainty evidence suggests that there is no increased risk of AEs with tofacitinib compared to placebo. However, we are uncertain about the effect of tofacitinib on SAEs due to the low number of events. Further studies are required to look at the long-term effectiveness and safety of using tofacitinib and other oral JAK inhibitors as maintenance ...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
Abstract Interleukin-6 (IL-6) is a pleiotropic pro-inflammatory cytokine. Its deregulation is associated with chronic inflammation, and multifactorial auto-immune disorders. It mediates its biological roles through a hexameric complex composed of IL-6 itself, its receptor IL-6R, and glycoprotein 130 (IL-6/IL-6R/gp130). This complex, in turn, activates different signaling mechanisms (classical and trans-signaling) to execute various biochemical functions. The trans-signaling mechanism activates various pathological routes, like JAK/STAT3, Ras/MAPK, PI3K-PKB/Akt, and regulation of CD4+ T cells and VEGF levels, which...
Source: Bioorganic and Medicinal Chemistry - Category: Chemistry Authors: Tags: Bioorg Med Chem Source Type: research
Publication date: Available online 17 December 2019Source: Pharmacological ResearchAuthor(s): Robert RoskoskiABSTRACTBecause genetic alterations including mutations, overexpression, translocations, and dysregulation of protein kinases are involved in the pathogenesis of many illnesses, this enzyme family is currently the subject of many drug discovery programs in the pharmaceutical industry. The US FDA approved four small molecule protein kinase antagonists in 2019; these include entrectinib, erdafitinib, pexidartinib, and fedratinib. Entrectinib binds to TRKA/B/C and ROS1 and is prescribed for the treatment of solid tumor...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
More News: Arthritis | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Chemistry | Heart | Inflammatory Bowel Disease | Molecular Biology | Nanotechnology | Rheumatoid Arthritis | Rheumatology